Although concrete evidence supports the superiority of mineralocorticoid receptor antagonists over alpha- and beta-blockers for patients with resistant hypertension, there is a lack of evidence regarding the use of central acting drugs in such patients. The gene discussed is NR3C2; the disease is hypertensive disorder.